AlloGen-LI
PreclinicalSmall molecule
AlloGen-LI is one of 5 small molecule programs targeting Spinal Stenosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Spinal Stenosis
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Marcaine
IInnocoll
Approved
Cytotec
PfizerPreclinical
Depomedrol
IIsfahan University of Medical Sciences
Preclinical
AlloGen-LI
UUniversity of Southern California
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AlloGen-LI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details